2023 Application

The application for the 2023 NINDS Clinical Trials Methodology Course (CTMC) is currently open for the 2023 cohort. This will be the last course year under the current grant funding. 


The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials. 

Course:

There is a combination of distance learning activities and a REQUIRED residential course, along with small group mentorship from experienced clinical trialists and biostatisticians. The residential part of the course will be held in June in 2023, Ann Arbor, MI. Funding for travel (within the US) and accommodations will be provided for participants.

Who Should Apply?

Qualified applicants from clinical disciplines focused on neurological disease or injury (including, but not limited to pediatric and rare diseases), along with biostatisticians working on projects with clinical neuroscience researchers should apply. All preliminary trial ideas are encouraged, but it is REQUIRED that protocols be focused on the clinical neurosciences. Trainees should have content area mentors to assist them with the science and implementation of their project. A small number of projects may qualify for additional work using clinical trial simulation.

Application:

2023 CTMC Application Instructions:

Google Doc

PDF

 

DEADLINE:

The application submission deadline is February 6th, 2023 at 9am, Eastern Time. Application forms and additional details are available on the course website: https://siren.network/training/ctmc. Early applications may be considered for early acceptance.

Have Questions?

Please review our FAQs. Please reach out to NINDS‐CTMC‐Info@umich.edu or William Meurer, MD, MS with any additional questions.

Thank you.

The NINDS Clinical Trials Methodology Course is supported by the NeuroNEXT DCC Grant Number U01 NS077352 and is administered by the University of Michigan, the University of Iowa, and Los Angeles BioMed. Additional support is provided by the American Academy of Neurology.